Medical Affairs AI Solutions

Territory management and KOL prioritization. AI-powered KOL mapping analyzes publication records, clinical trial leadership, congress presentation history, guideline committee memberships, and social network influence to generate quantitative influence scores and engagement priority rankings. These scores help MSL directors allocate field resources to the highest-impact scientific relationships.

Pre-call planning. Before every HCP interaction, AI assembles comprehensive pre-call briefs by aggregating CRM interaction history, recent publications, ongoing clinical trials, and recent congress presentations — transforming pre-call preparation from hours of manual research into a curated scientific briefing delivered in minutes.

Scientific exchange documentation. AI-assisted documentation uses NLP to structure free-text field notes into standardized formats, automatically tagging interactions by therapeutic area, product, discussion topic, and insight category. Medical insights aggregated across the MSL team reveal clinical practice patterns and unmet needs that would be invisible in individual CRM records.

KOL engagement plans and compliance. AI generates engagement plans for priority KOLs based on scientific profile and medical plan objectives, filtered through compliance rules consistent with OIG Compliance Program Guidance and applicable anti-kickback regulations.

Case intake and triage. Adverse event reports arrive from spontaneous reports, clinical trial databases, literature monitoring, and increasingly from social media and patient support programs. AI extracts case information from unstructured sources, identifies minimum ICSR validity criteria, and flags potential duplicate cases using probabilistic matching against the existing safety database.

MedDRA coding and medical review. AI maps verbatim adverse event descriptions to MedDRA Preferred Terms and Lowest Level Terms with high accuracy. For causality assessment, AI evaluates temporal relationship, biological plausibility, dechallenge/rechallenge information, and consistency with the Reference Safety Information using the CIOMS/WHO methodology and Naranjo algorithm, generating preliminary assessments for safety physician review.

Narrative generation and regulatory submission. AI generates draft ICSR narratives from structured case data, following the organization's standard templates. For regulatory submission, AI manages reporting timelines across all applicable authorities, generates E2B(R3)-compliant electronic case reports, and tracks acknowledgments and follow-up requests.

Signal detection. AI applies quantitative signal detection methods including PRR, ROR, BCPNN, and MGPS across the safety database and integrates with FDA FAERS and EudraVigilance, managed through a structured process aligned with GVP Module IX.

Systematic literature reviews and gap analysis. AI automates systematic literature reviews per PRISMA, screening thousands of abstracts, assigning relevance scores, identifying duplicates across databases, and generating PRISMA flow diagrams. Gap analysis then compares the existing evidence base against the product's clinical data package and strategic objectives to identify high-priority publication opportunities.

Congress strategy and abstract submission. AI analyzes historical acceptance rates for specific congress sessions, competitor abstract patterns, audience demographics, and congress theme alignment to recommend optimal submission strategies. For poster preparation, AI ensures adherence to congress formatting requirements and generates narrative summaries that enhance impact during presentation sessions.

Manuscript development support. AI generates structured first drafts from clinical study reports per applicable reporting guidelines — CONSORT for randomized trials, STROBE for observational studies — cross-referencing claims against underlying data and flagging statistical inconsistencies.

Publication impact measurement. AI tracks citation counts, journal tier distribution, Altmetric attention scores, guideline citations, and formulary dossier inclusions — correlating publication activities with downstream changes in prescribing patterns and treatment guidelines.

Scientific exchange compliance. AI classifies incoming requests as solicited or unsolicited, verifies that responses to off-label questions are channeled through appropriate medical personnel, ensures responses include fair balance and disclosure about unapproved use, and documents the complete interaction chain for audit — consistent with FDA guidance on manufacturer communications with payors.

Sunshine Act and transparency reporting. AI automates tracking and aggregation of transfers of value across all medical affairs touchpoints, reconciles planned versus actual payments, generates required data formats for CMS submission, and manages analogous transparency reporting under EFPIA disclosure requirements in Europe.

FCPA and global anti-corruption compliance. AI maintains fair market value databases for HCP compensation across countries and specialties, screens proposed engagement terms against local benchmarks, and identifies patterns of payments that could raise compliance red flags — generating the documentation required to demonstrate legitimate scientific purpose for each engagement.

21 CFR Part 11 audit trails. Every AI recommendation, human decision, approval, and content modification is captured with user identity, timestamp, action taken, and rationale. For AI-assisted activities, the audit trail additionally captures the model version, input data, generated recommendation, confidence score, and whether the human accepted, modified, or rejected the AI suggestion.